银诺医药-B在澳大利亚完成依苏帕格鲁肽α用于治疗肥胖和超重的II期临床试验的首例患者给药

Group 1 - The company has announced the completion of the first patient dosing in a Phase II clinical trial for Isupegadex α aimed at treating obesity and overweight in Australia [1] - The clinical trial is expected to enroll approximately 200 participants [1]